Dermata Therapeutics Inc DRMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DRMA is a good fit for your portfolio.
News
-
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
-
Dermata to Present at the Emerging Growth Conference on April 3, 2024
-
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
-
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Trading Information
- Previous Close Price
- $0.34
- Day Range
- $0.32–0.35
- 52-Week Range
- $0.23–3.68
- Bid/Ask
- $0.32 / $0.35
- Market Cap
- $2.14 Mil
- Volume/Avg
- 28,516 / 147,188
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.dermatarx.com
Valuation
|
Metric
|
DRMA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DRMA
|
|---|---|
Quick Ratio | 4.59 |
Current Ratio | 4.91 |
Interest Coverage | — |
Quick Ratio
DRMA
Profitability
|
Metric
|
DRMA
|
|---|---|
Return on Assets (Normalized) | −90.33% |
Return on Equity (Normalized) | −104.19% |
Return on Invested Capital (Normalized) | −107.73% |
Return on Assets
DRMA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qbgyvrcfh | Sycx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tkldvsjd | Htyqhr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xglgkxq | Vrqygv | $98.1 Bil | |
MRNA
| Moderna Inc | Jnwvjxhg | Prw | $39.1 Bil | |
ARGX
| argenx SE ADR | Lvxnhtj | Lnt | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Hxbpsvq | Hgfz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lcqdvbkpt | Jvhlsms | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rmynljvc | Zrwsff | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fvkwsjhc | Xcngj | $12.5 Bil | |
INCY
| Incyte Corp | Yqwnwnrt | Rddyn | $11.9 Bil |